Celyad Oncology Sa Revenue Growth Rates (CYAD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Celyad Oncology Sa  (NASDAQ: CYAD)
 

CYAD's Revenue Growth by Quarter and Year

Celyad Oncology Sa's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYAD Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 0.00
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00

CYADs Annual Revenue
Celyad Oncology Sa's Revenue in the fiscal year 2022 $ 0.00 millions
Celyad Oncology Sa's Revenue in the fiscal year 2021 $ 0.00 millions
Celyad Oncology Sa's Revenue in the fiscal year 2020 $ 0.01 millions
Celyad Oncology Sa's Revenue in the fiscal year 2019 $ 0.01 millions
Celyad Oncology Sa's Revenue in the fiscal year 2018 $ 3.49 millions




CYAD Revenue fourth quarter 2022 Y/Y Growth Comment
Celyad Oncology Sa in the fourth quarter 2022 recorded of $ 0.00 millions.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 125 other companies have achieved higher Revenue growth. While Celyad Oncology Sa' s Revenue no change of 0% ranks overall at the positon no. 2027 in the fourth quarter 2022.


CYAD Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - 0 % -99.71 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - 0 % -

Financial Statements
Celyad Oncology Sa's fourth quarter 2022 Revenue $ 0.00 millions CYAD's Income Statement
Celyad Oncology Sa's fourth quarter 2021 Revenue $ 0.00 millions Quarterly CYAD's Income Statement


CYAD Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - 0 % -


Back to CYAD Growth rate Comparisons >> Back to CYAD Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #126
Healthcare Sector #294
Overall #2027

Revenue Y/Y Growth Statistics
High Average Low
15.33 % -33.71 % -99.81 %
(Dec 31 2018)   (Dec 31 2019)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #126
Healthcare Sector #294
Overall #2027
Revenue Y/Y Growth Statistics
High Average Low
15.33 % -33.71 % -99.81 %
(Dec 31 2018)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Celyad Oncology Sa's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYAD's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYAD's IV. Quarter Q/Q Revenue Comment


Celyad Oncology Sa's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Dec 31 2018)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.01 $ 0.01 $ 3.49
Y / Y Revenue Growth (TTM) - - -16.67 % -99.81 % 15.33 %
Year on Year Revenue Growth Overall Ranking # 2027 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) - - -16.67 % -99.81 % 15.33 %
Seq. Revenue Growth (TTM) Overall Ranking # 2027 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
In the Dec 31 2022 period, Celyad Oncology Sa's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 293 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2027.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 294
Overall # 2027

Revenue TTM Y/Y Growth Statistics
High Average Low
15.33 %
 -33.71 %
-99.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 126
Sector # 294
S&P 500 # 2027
Cumulative Revenue growth Comment
In the Dec 31 2022 period, Celyad Oncology Sa's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 293 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2027.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 294
Overall # 2027

Revenue TTM Y/Y Growth Statistics
High Average Low
15.33 %
-33.71 %
-99.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 126
Sector # 294
S&P 500 # 2027




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYAD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Celyad Oncology Sa Revenue Growth Rates (CYAD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Celyad Oncology Sa (CIK 1637890).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-23-078009
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Celyad Oncology Sa’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.